Skip to main content
Peter O'Donnell, MD, Oncology, Chicago, IL

Peter Hugh O'Donnell MD

Genitourinary Oncology, Hematologic Oncology


Assistant Professor of Medicine, University of Chicago, Pritzker School of Medicine

Join to View Full Profile
  • 5841 S Maryland Ave# MC2115Chicago, IL 60637

  • Phone+1 773-702-4400

  • Fax+1 773-702-3163

Dr. O'Donnell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • University of Chicago
    University of ChicagoFellowship, Hematology and Medical Oncology, 2006 - 2010
  • University of Chicago
    University of ChicagoResidency, Internal Medicine, 2004 - 2006
  • University of North Carolina Hospitals
    University of North Carolina HospitalsResidency, Internal Medicine, 2003 - 2004
  • University of Chicago Division of the Biological Sciences The Pritzker School of Medicine
    University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2003

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 2006 - 2026
  • NC State Medical License
    NC State Medical License 2003 - 2004
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • KEYNOTE-052: Phase 2 study evaluating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)— Updated response and survival results. 
    2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

  • ASCO Annual Meeting Returns to Chicago, Celebrates New Progress in Cancer
    ASCO Annual Meeting Returns to Chicago, Celebrates New Progress in CancerJune 15th, 2022
  • UTSW Finds Potential Key to Predict Immunotherapy Toxicity
    UTSW Finds Potential Key to Predict Immunotherapy ToxicityAugust 15th, 2023

Grant Support

  • Pharmacogenomics to Catalyze Decision Support in Oncology CareUNIVERSITY OF CHICAGO2023–2028
  • Integrative Analyses of Clinical Pharmacogenetic Data to Prevent Hospital Readmission in Real-World Health SystemsENDEAVOR HEALTH CLINICAL OPERATIONS2024–2026
  • Integrative Analyses of Clinical Pharmacogenetic Data to Prevent Hospital Readmission in Real-World Health SystemsENDEAVOR HEALTH CLINICAL OPERATIONS2024–2026
  • Clinical TherapeuticsUNIVERSITY OF CHICAGO1978–2025

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: